Home
ACR–ACNM–SNMMI–SPR–STR PRACTICE PARAMETER FOR THE PERFORMANCE OF PULMONARY SCINTIGRAPHY
Revised 2023 (Resolution 26)
PREAMBLE
I. INTRODUCTION
II. INDICATIONS AND CONTRAINDICATIONS
III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL
IV. SPECIFICATIONS OF THE EXAMINATION
IV. SPECIFICATIONS OF THE EXAMINATION
A. Pulmonary Perfusion Imaging
1. Radiopharmaceutical—Technetium-99m–labeled macroaggregated albumin (MAA) [12,13]
a. Administered Activity—Perfusion After Ventilation
IV. SPECIFICATIONS OF THE EXAMINATION
A. Pulmonary Perfusion Imaging
1. Radiopharmaceutical—Technetium-99m–labeled macroaggregated albumin (MAA) [12,13]
b. Administered Activity—Ventilation After Perfusion or Perfusion Only
IV. SPECIFICATIONS OF THE EXAMINATION
A. Pulmonary Perfusion Imaging
1. Radiopharmaceutical—Technetium-99m–labeled macroaggregated albumin (MAA) [12,13]
c. MAA Particle Size and Administered Number of Particles
IV. SPECIFICATIONS OF THE EXAMINATION
A. Pulmonary Perfusion Imaging
1. Radiopharmaceutical—Technetium-99m–labeled macroaggregated albumin (MAA) [12,13]
d. Radiopharmaceutical Administration
IV. SPECIFICATIONS OF THE EXAMINATION
A. Pulmonary Perfusion Imaging
1. Radiopharmaceutical—Technetium-99m–labeled macroaggregated albumin (MAA) [12,13]
e. Imaging
IV. SPECIFICATIONS OF THE EXAMINATION
B. Pulmonary Ventilation Imaging
1. Radiopharmaceutical—Technetium-99m-labeled diethylene-triamine pentacetic acid (DTPA) aerosol
IV. SPECIFICATIONS OF THE EXAMINATION
B. Pulmonary Ventilation Imaging
2. Radiopharmaceutical—Xenon-133
IV. SPECIFICATIONS OF THE EXAMINATION
B. Pulmonary Ventilation Imaging
2. Radiopharmaceutical—Xenon-133
a. Administered activity
IV. SPECIFICATIONS OF THE EXAMINATION
B. Pulmonary Ventilation Imaging
2. Radiopharmaceutical—Xenon-133
b. Imaging
IV. SPECIFICATIONS OF THE EXAMINATION
C. Other Considerations
V. DOCUMENTATION
VI. EQUIPMENT SPECIFICATIONS
VII. RADIATION SAFETY IMAGING
VIII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION
ACKNOWLEDGEMENTS
REFERENCES